I think it warrants making a new publication here, 
BIIB has flashed a buy signal with tremendously good reward to risk, as it can resume the long term trend that can take it over $1600-2600 over time. Phase 3 clinical trials have gone really well for their Alzheimer's treatment 'Aduhelm', putting it in line with results obtained by 
LLY's drug 'Donanemab'. I was long LLY and have been trading in and out of BIIB trying to time the end of the long slide since the FDA approval news came out. I think the time is now, to get in and sit tight. I've banked my LLY exposure, but both companies will likely do well with their Alzheimer's treatments going forward and have solid trends, but the reward to risk favors BIIB, so I'm only long Biogen currently.
Best of luck!
Cheers,
Ivan.
BIIB has flashed a buy signal with tremendously good reward to risk, as it can resume the long term trend that can take it over $1600-2600 over time. Phase 3 clinical trials have gone really well for their Alzheimer's treatment 'Aduhelm', putting it in line with results obtained by LLY's drug 'Donanemab'. I was long LLY and have been trading in and out of BIIB trying to time the end of the long slide since the FDA approval news came out. I think the time is now, to get in and sit tight. I've banked my LLY exposure, but both companies will likely do well with their Alzheimer's treatments going forward and have solid trends, but the reward to risk favors BIIB, so I'm only long Biogen currently.Best of luck!
Cheers,
Ivan.
Note
Trade fermée: ordre d’arrêt atteint
Public, timestamped track record. Free month of the desk: ivanlabrie.netlify.app
Publications connexes
Clause de non-responsabilité
Les informations et publications ne sont pas destinées à être, et ne constituent pas, des conseils ou recommandations financiers, d'investissement, de trading ou autres fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.
Public, timestamped track record. Free month of the desk: ivanlabrie.netlify.app
Publications connexes
Clause de non-responsabilité
Les informations et publications ne sont pas destinées à être, et ne constituent pas, des conseils ou recommandations financiers, d'investissement, de trading ou autres fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.